Cargando…

Erratum to “Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome”

Detalles Bibliográficos
Autores principales:	Alonso-Bello, Cesar Daniel, Jiménez-Martínez, María del Carmen, Vargas-Camaño, María Eugenia, Hierro-Orozco, Sagrario, Ynga-Durand, Mario Alberto, Berrón-Ruiz, Laura, Alcántara-Montiel, Julio César, Santos-Argumedo, Leopoldo, Andrea Herrera-Sánchez, Diana, Lozano-Patiño, Fernando, Castrejón-Vázquez, María Isabel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895602/ https://www.ncbi.nlm.nih.gov/pubmed/33628541 http://dx.doi.org/10.1155/2021/2361360

Ejemplares similares

Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome
por: Alonso-Bello, Cesar Daniel, et al.
Publicado: (2019)

The Effects of Alternate-Day Corticosteroids in Autoimmune Disease Patients
por: Chaia-Semerena, Genny Margarita, et al.
Publicado: (2020)

Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review
por: Lan, Jun, et al.
Publicado: (2022)

Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
por: Pennington, Luke F., et al.
Publicado: (2016)

Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit
por: Castrejón Vázquez, Maria Isabel, et al.
Publicado: (2019)

Inhibition of IgE and IgE/anti-IgE mediated responses in mast cells by Omalizumab
por: Kulka, M, et al.
Publicado: (2010)

Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE
por: R, Divya, et al.
Publicado: (2020)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Hyper IgE syndrome
por: Dang, Yun, et al.
Publicado: (2014)

Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy
por: Kariyawasam, Harsha H, et al.
Publicado: (2020)

Hyper-IgE and Carcinoma in CADINS Disease
por: Pietzsch, Leonora, et al.
Publicado: (2022)

A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma
por: D’Amato, Gennaro, et al.
Publicado: (2007)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

Current and future applications of the anti-IgE antibody omalizumab
por: Incorvaia, Cristoforo, et al.
Publicado: (2008)

An update on the hyper-IgE syndromes
por: Yong, Patrick FK, et al.
Publicado: (2012)

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells
por: Chan, Marcia A, et al.
Publicado: (2013)

272 Gender and Different Prevalence in Asthma Treatment With Anti-IGE (Omalizumab)
por: Patella, Vincenzo, et al.
Publicado: (2012)

Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab
por: Davies, Anna M., et al.
Publicado: (2017)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
por: Tajiri, Tomoko, et al.
Publicado: (2023)

IgG and IgE Autoantibodies to IgE Receptors in Chronic Spontaneous Urticaria and Their Role in the Response to Omalizumab
por: Maronese, Carlo Alberto, et al.
Publicado: (2023)

Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review
por: D’Amato, Gennaro, et al.
Publicado: (2014)

HYPER IgE SYNDROME WITH UMBILICAL HERNIA
por: Hiremath, N C, et al.
Publicado: (2009)

Clinical Manifestations of Hyper IgE Syndromes
por: Freeman, Alexandra F., et al.
Publicado: (2010)

Autosomal-Recessive Hyper-IgE Syndrome
por: Liza, Mohapatra, et al.
Publicado: (2018)

Pediatric anaphylaxis and hyper IgE syndrome
por: Dosanjh, Amrita
Publicado: (2017)

Staphylococcus aureus and Hyper-IgE Syndrome
por: Park, Bonggoo, et al.
Publicado: (2020)

Relevance of Eosinophilia and Hyper-IgE in Immigrant Children
por: Belhassen-García, Moncef, et al.
Publicado: (2014)

Hyper IgE Syndrome and Renal Cell Carcinoma
por: Patel, Neel H., et al.
Publicado: (2017)

Clinical Profile of Hyper-IgE Syndrome in India
por: Saikia, Biman, et al.
Publicado: (2021)

Hyper IgE Syndrome in an Isolated Population in Israel
por: Lachover-Roth, Idit, et al.
Publicado: (2022)

The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Glycoproteomic studies of IgE from a novel hyper IgE syndrome linked to PGM3 mutation
por: Wu, Gang, et al.
Publicado: (2015)

Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization
por: Mitropoulou, Alkistis N., et al.
Publicado: (2020)

Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
por: Humbert, Marc, et al.
Publicado: (2013)

Serum free IgE guided dose reduction of omalizumab: a case report
por: Gon, Yasuhiro, et al.
Publicado: (2017)

Brain Abscess and Keratoacanthoma Suggestive of Hyper IgE Syndrome
por: Alyasin, Soheyla, et al.
Publicado: (2015)

Liver abscess in a boy with hyper IgE syndrome
por: Nandy, Sneha, et al.
Publicado: (2016)

Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2019)

The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
por: Gasser, Pascal, et al.
Publicado: (2020)

Profound differences in IgE and IgG recognition of micro‐arrayed allergens in hyper‐IgE syndromes
por: Garib, Victoria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ueqfj7vji9p108fsream20lbel